This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017;31:1087–95.
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood. 2020; blood.2020004907. https://doi.org/10.1182/blood.2020004907.
Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018;11:25.
Lai Y, Weng J, Wei X, Qin L, Lai P, Zhao R, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells. Leukemia. 2018;32:801–8.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (No. 81870121); Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515010094); and the Project of Administration of Traditional Chinese Medicine of Guangdong Province (20191008).
Author information
Authors and Affiliations
Contributions
J Weng, X Du, P Li, and P Lai conceived and designed the study. P Lai, X Chen, L Qin, Z Jiang, C Luo, X Huang, S Wu, W Ling, Y Wang, J Wang, C Deng, and L Huang performed the main experiments and analyses. L Zeng, Z Lu, L Zhong, P Liao, M Li, D Chen, P Wu, and S Geng assisted in diagnostic interpretation of patient samples, and clinical monitor of patients’ condition. P Lai, J Weng, X Du, and P Li wrote the paper. Z Tang, and D Pei provide conceptual advice and revised the paper. All authors read and approved the final paper.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lai, P., Chen, X., Qin, L. et al. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia 34, 2790–2793 (2020). https://doi.org/10.1038/s41375-020-0952-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0952-4
This article is cited by
-
CD19-chimeric-antigen-receptor-T2-cell-therapy-Guangdong-Zhaotai-InVivo
Reactions Weekly (2020)